NRF3 decreases during melanoma carcinogenesis and Is an independent prognostic marker in melanoma |
|
Author: | Immonen, Anni1,2; Haapasaari, Kirsi-Maria1,2,3; Skarp, Sini4; |
Organizations: |
1Cancer Research and Translational Medicine Research Unit, University of Oulu, Oulu, Finland 2Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland 3Department of Pathology, Oulu University Hospital, Oulu, Finland
4Infrastructure for Population Studies, Faculty of Medicine, University of Oulu, Oulu, Finland
5Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland |
Format: | article |
Version: | published version |
Access: | open |
Online Access: | PDF Full Text (PDF, 2.2 MB) |
Persistent link: | http://urn.fi/urn:nbn:fi-fe2022093060497 |
Language: | English |
Published: |
Hindawi,
2022
|
Publish Date: | 2022-09-30 |
Description: |
AbstractThe prognostic significance of the major redox regulator, nuclear factor erythroid-2-related factor 2 (NRF2), is recognized in many cancers, but the role of NRF3 is not studied. Analysis from the Gene Expression Omnibus datasets showed that NRF3 mRNA levels increased from benign to dysplastic naevi (p = 0.04). We characterized the immunohistochemical expression of NRF3 in 81 naevi, 67 primary skin melanomas, and 51 lymph node metastases. The immunohistochemical expression of cytoplasmic NRF3 decreased from benign to dysplastic naevi (p < 0.001) and further to primary melanomas (p < 0.001). High cytoplasmic NRF3 protein expression in pigment cells of the primary melanomas associated with worse melanoma-specific survival in multivariate analysis, specifically in the subgroup of patients with the lymph node metastases at the time of diagnosis (hazard ratio 3.179; 95% confidence interval 1.065-9.493; p = 0.038). Intriguingly, we did not observe associations between NRF3 and the traditional prognostic factors such as Breslow thickness, ulceration, or stage. Together, this data represents the primary description about the role of NRF3 in pigment tumours that is worthy of further explorations. see all
|
Series: |
Oxidative medicine and cellular longevity |
ISSN: | 1942-0900 |
ISSN-E: | 1942-0994 |
ISSN-L: | 1942-0900 |
Volume: | 2022 |
Article number: | 2240223 |
DOI: | 10.1155/2022/2240223 |
OADOI: | https://oadoi.org/10.1155/2022/2240223 |
Type of Publication: |
A1 Journal article – refereed |
Field of Science: |
3122 Cancers |
Subjects: | |
Funding: |
We thank the Finnish Dermatopathology Association and Finnish Society for Oncology, Melanoma group, for the financial support in the form of personal grants (HRT) and Medical Research Center Oulu in the form of working grants (HRT). |
Copyright information: |
© 2022 Anni Immonen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
https://creativecommons.org/licenses/by/4.0/ |